전체 프로그램

ADC 890 · Antibody 4097 · CGT 2985 · 다음 갱신 D-6 · 마지막 9월 2일

PopularRecently updatedCuratedMost trialsNeeds refreshORRLatestPhase 3FDA approved3 programs
AntibodyLimited DatastaleEli LillyPhase 2

mCapOX plus Cetuximab (mCapOX plus Cetuximab)

Colo-rectal Cancer; Capecitabine · Colorectal Cancer (CRC)

#ColorectalCancerCRC#Antibody#Phase2#monoclonal-antibody#Colo-rectalCancer+2
Trials 2Status Active
AntibodyLimited DatastaleEli LillyPhase 3

Experimental: mXELOX plus cetuximab (Experimental: mXELOX plus cetuximab)

Colo-rectal Cancer · Colo-rectal Cancer

#Colo-rectalCancer#Antibody#Phase3#monoclonal-antibody#Eli
Trials 1Status Active
AntibodyLimited DatastaleRochePhase 2

Trifluridine/tipiracil (TAS-102, Trifluridine/tipiracil, Trifluridine/tipiracil (TAS-102) plus bevacizumab)

Colo-rectal Cancer; Third-line and Beyond Therapy · Colo-rectal Cancer

#Colo-rectalCancer#Antibody#Phase2#monoclonal-antibody#Third-lineandBeyondTherapy+1
Trials 1Status Recruiting